Archive for the ‘Cancer Research’ Tag

New Genetic Studies Opening Up New Paths for Lung Cancer Research   Leave a comment

Here’s some hopeful news for cancer researchers:

Professor Ramaswamy Govindan, of Washington University School of Medicine in St Louis, USA, who worked on two of the studies, said that the research gives scientists ‘a penthouse panoramic view’ of lung cancer, whereas before they had been only ‘looking through a keyhole’.

The papers – the first in an expected wave of ‘cataloguing studies’ – reveal a complex series of genetic changes across the genome, and identify lung cancer as a highly diverse or ‘heterogenous’ disease. New mutations discovered include those that allow tumours unrestricted growth, or that enable them to evade the body’s immune responses. Other mutations have been unearthed in genes involved in DNA repair mechanisms.


Posted September 19, 2012 by lymphomactivist in Research

Tagged with ,

How a Proton Accelerator Can Help Fight Cancer   Leave a comment

I don’t even really know what a proton accelerator is, but a doctor in St. Louis does, and he’s hoping to use one to get rid of tumors.

With traditional therapies like X-ray, a patient’s healthy tissues are often hit by radiation. This machine is so precise that doctors can hit tumors with higher doses–without damaging surrounding organs.

“For a tumor that’s near the eye, you don’t want to spray it with excess radiation,” said Dr. Bradley.

Until now, proton beam facilities in the United States would cost more than 150 million dollars and require the space of a football field. This machine cost 75 percent less and fits into a single room. While it could cost up to 20 percent more than traditional treatments, for some patients it could be worth it.

It sounds amazing, but I especially like the talk of how much smaller this one is than previous versions, when it still weighs 50 tons and takes up an entire room. It sounds so much like stuff you see about what people in the 1970s and 1980s were saying about computers that seem gargantuan to us compared to our smart phones.

Johnson & Johnson Partnering with Smaller Drug Makers to Find Breakthroughs   Leave a comment

Johnson & Johnson is paying Pharmacyclics $50 million in what is called a milestone payment as the small drug researcher works on a new drug to combat mantel cell lymphoma, one of the more rare forms of NHL.

Apparently the drug giant is doing this thing more and more, as it allows the large company to benefit from innovation and advanced research without taking on the high risks that come with such work. It also, of course, gives funding to smaller companies in desperate need for the money. All in all, it sounds like a great plan to me.

The important thing of course, is that the research looks promising. Here’s hoping!

The two companies, which partnered up at the end of last year, are working to develop a novel kinase inhibitor known as ibrutinib as a medicine for patients who have suffered a relapse of mantel cell lymphoma, one of the rarest forms of non-Hodgkin’s lymphomas or cancers of the body’s B cells.

The drug candidate is also being studied as a treatment for patients who have developed a resistence to other medicines.

Pharmacyclics, which is based in Sunnyvale, Calif., said it is eligible to receive up to $725 million more in funding as it advances work on the drug.

Researchers Discover Cause of a Type of NHL   Leave a comment

This is very good news. After all, you can’t find a cure for a disease until you know what causes it, can you? Dr. Sandrine Sander and Professor Klaus Rajewsky in Berlin have figured out the cause of Burkitt Lymphoma, an extremely fast growing form of non-Hodgkin’s lymphomas.

According to Dr. Sandrine Sander and Professor Klaus Rajewsky, Burkitt lymphoma originates from germinal centers of the lymphoid organs (Peyer’s patches in the small intestine, spleen and lymph nodes). The reaction by the germinal center is triggered by the B cells when antigens are detected. Once the reaction occurs, the B cells alter their DNA causing a highly specific antibody response against the antigen.

The B cell receptor (BCR) plays a vital role in the reaction process. In order to fully recognize the antigen and trigger an appropriate immune response, the DNA segments encoding the antibody must be altered and rearranged. During this complicated process, DNA breaks may occur and error-prone repair mechanisms may result in genetic mutations linked with cancer development.

Very well done. Which means that now they can get started on finding a cure for it. Let’s hope that they do.

Posted August 19, 2012 by lymphomactivist in NHL, Research

Tagged with , ,

A New Project to Protect Children from NHL   1 comment

Here’s an interesting bit of research from England. The charitable foundation Leukaemia & Lymphoma Research has funded a new research project designed to combat NHL specifically in children:

Dr Vikki Rand was awarded a prestigious ‘Bennett Fellowship’ by the charity to establish a research team at Newcastle University. They will use cutting-edge technology to scan the entire genome of an aggressive set of cancers known as B-cell non-Hodgkin lymphomas, in order to identify underlying genetic abnormalities within the cancer cells.

Lymphoma is the third most common cancer of children in the UK, but the clinical relevance of differences between the two main types of lymphoma, Burkitt lymphoma and diffuse large B-cell lymphoma, has still not been defined. Treatment is the same for both groups.

Posted August 16, 2012 by lymphomactivist in NHL, Research

Tagged with , , ,

Genome Senquencing of Lymphomas Progressing   1 comment

This is very good news, it seems to me.

Researchers at the Mayo Clinic have completed the first genome-wide sequencing of peripheral T cell lymphomas, which will allow doctors to delve into this cancer of the immune system that account for 12% of all non-hodgkin’s lymphomas and are among the most deadly. Fewer than 35 percent of patients live five years beyond diagnosis. Andrew Feldman was the lead investigator and said of the breakthrough:

“Every time I diagnose a peripheral T-cell lymphoma, I know that two out of three patients will succumb to that lymphoma,” says Dr. Feldman. “That’s a very unsatisfying feeling, and I hope that our research can help change those statistics.”

How little, in fact, doctors understand about this type of cancer is summed up in the name of the most-common form of the disease:

“The most common type of T-cell lymphoma is called ‘not otherwise specified.’ It’s basically a wastebasket diagnosis because we don’t understand enough about the specific genetic abnormalities to be able to pinpoint subtypes of T-cell lymphomas that might trigger different treatments by the treating oncologist,” says Dr. Feldman.

Let’s hope his work will lead to better days ahead.

Posted August 7, 2012 by lymphomactivist in NHL, Research

Tagged with , , ,

Needed Research into Rare Form of NHL   Leave a comment

Splenic Marginal Zone Lymphoma (SMZL) is a rare form of non-Hodgkin’s Lymphoma that accounts for less than 3% of all cases of lymphoma. As a result, much less time has been spent on researching the cancer and, of course, much less is known about it.

Thankfully, though, England’s University of Southampton has gotten funding that will allow it to use state-of-the-art technology to search through a patient’s genes and determine the mutations that cause SMZL. With that knowledge the researchers aim to reveal what they refer to as the “genetic signs” that are linked to particularly bad prognoses. They will then be able to help doctors direct treatment accordingly.

The head of the research team, Dr. Jonathan Strefford, says:

“Finding these gene mutations will increase our understanding of how SMZL progresses and allow us to predict patient prognosis. These predictions can then be taken into account by doctors to ensure that those with a more aggressive disease are given the treatment that they need.”

Posted August 3, 2012 by lymphomactivist in NHL, Research

Tagged with , , ,